Massar Capital Management LP Buys New Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Massar Capital Management LP purchased a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 3,080 shares of the medical instruments supplier's stock, valued at approximately $284,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC raised its stake in shares of LeMaitre Vascular by 234.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock worth $39,000 after purchasing an additional 293 shares during the last quarter. CBIZ Investment Advisory Services LLC raised its stake in shares of LeMaitre Vascular by 38.5% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock worth $39,000 after purchasing an additional 117 shares during the last quarter. KBC Group NV raised its stake in shares of LeMaitre Vascular by 58.4% in the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock worth $102,000 after purchasing an additional 410 shares during the last quarter. Huntington National Bank raised its stake in shares of LeMaitre Vascular by 64.9% in the fourth quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock worth $107,000 after purchasing an additional 455 shares during the last quarter. Finally, Empowered Funds LLC purchased a new position in shares of LeMaitre Vascular in the fourth quarter worth about $150,000. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Price Performance

NASDAQ LMAT traded down $0.15 during mid-day trading on Friday, hitting $91.61. The stock had a trading volume of 106,920 shares, compared to its average volume of 161,776. LeMaitre Vascular, Inc. has a twelve month low of $64.44 and a twelve month high of $109.58. The firm's 50 day moving average is $86.90 and its 200 day moving average is $93.45. The stock has a market capitalization of $2.07 billion, a price-to-earnings ratio of 50.06, a PEG ratio of 2.22 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, meeting analysts' consensus estimates of $0.49. The business had revenue of $55.81 million during the quarter, compared to analysts' expectations of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. As a group, equities research analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th were given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.87%. This is a boost from LeMaitre Vascular's previous quarterly dividend of $0.16. The ex-dividend date of this dividend was Thursday, March 13th. LeMaitre Vascular's dividend payout ratio is 41.24%.

Insider Activity

In other news, insider Trent G. Kamke sold 2,009 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the transaction, the insider now owns 5,564 shares of the company's stock, valued at approximately $456,915.68. This trade represents a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 10.79% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on LMAT shares. Wells Fargo & Company started coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price objective for the company. Barrington Research lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Lake Street Capital raised their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Finally, Oppenheimer lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Five investment analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, LeMaitre Vascular currently has an average rating of "Moderate Buy" and a consensus price target of $98.14.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.